Disc Medicine Stock Today
| IRON Stock | 64.50 0.46 0.71% |
Performance9 of 100
| Odds Of DistressLess than 26
|
Disc Medicine is selling at 64.50 as of the 26th of November 2024; that is 0.71% down since the beginning of the trading day. The stock's open price was 64.96. Disc Medicine has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Disc Medicine are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 31st of January 2024 and ending today, the 26th of November 2024. Click here to learn more.
Moving against Disc Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Disc Stock Highlights
| President CEO | Esq JD |
| Old Name | Alderon Iron Ore Corp |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
Disc Medicine (IRON) is traded on NASDAQ Exchange in USA. It is located in 321 Arsenal Street, Watertown, MA, United States, 02472 and employs 82 people. Disc Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.93 B. Disc Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.76 M outstanding shares of which 1.63 M shares are currently shorted by private and institutional investors with about 6.0 trading days to cover.
Disc Medicine generates negative cash flow from operations
Check Disc Medicine Probability Of Bankruptcy
Ownership AllocationDisc Medicine holds a total of 29.76 Million outstanding shares. The majority of Disc Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Disc Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Disc Medicine. Please pay attention to any change in the institutional holdings of Disc Medicine as this could imply that something significant has changed or is about to change at the company. Also note that almost three million thirty-five thousand two hundred eighty-five invesors are currently shorting Disc Medicine expressing very little confidence in its future performance.
Check Disc Ownership Details
Disc Medicine Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Disc Medicine market risk premium is the additional return an investor will receive from holding Disc Medicine long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0984 | |||
| Jensen Alpha | 0.5134 | |||
| Total Risk Alpha | (0.17) | |||
| Sortino Ratio | 0.134 |
Disc Stock Against Markets
Disc Medicine Corporate Management
| Jonathan Yu | Chief Officer | Profile | |
| Rahul Kaushik | Chief Officer | Profile | |
| Joanne CPA | Chief Officer | Profile | |
| William MD | Chief Officer | Profile | |
| Pamela MPH | Chief Officer | Profile | |
| Jean CPA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Disc Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Disc Stock, please use our How to Invest in Disc Medicine guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Disc Medicine. If investors know Disc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Disc Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Disc Medicine is measured differently than its book value, which is the value of Disc that is recorded on the company's balance sheet. Investors also form their own opinion of Disc Medicine's value that differs from its market value or its book value, called intrinsic value, which is Disc Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Disc Medicine's market value can be influenced by many factors that don't directly affect Disc Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Disc Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Disc Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Disc Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.